Prescient Therapeutics’ PTX-100 trial expands to top US cancer centre
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...
Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Q&A Update with Dr James Campbell Reach Markets recently interviewed Dr James Campbell...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO and Managing Director, James McDonnell, held...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.